| 摘要 |
The present invention relates to a pharmaceutical composition for preventing or treating ocular surface disease, containing, as an active ingredient, GQDGLAGPK which is a collagen-type II α1-based peptide isolated from cartilage cell-derived extracellular matrix. In an alkali burning-induced animal model treated with peptide GQDGLAGPK, reduction in keratoleukoma and a decrease in the expression of vascular endothelial growth factor (VEGF), and CD31, which are angiogenic factors, have been detected. In addition, an amount of macrophage, tumor necrosis factor (TNF) α, intercellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1, and matrix metalloproteinases (MMP)-9, which are indicated as inflammatory markers, decreases, and the expression of NF-κB which is an inflammation-inducing factor is inhibited as well. Therefore, the peptide GQDGLAGPK of the present invention can be used as a pharmaceutical composition for preventing or treating corneal disease which is ocular surface disease. |
